Rate My Professor Claudio Dos Santos

Dos Santos has co-authored several peer-reviewed publications in bioscience and environmental research. In 2024, he contributed to 'Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis,' published in the Journal of Cystic Fibrosis (Volume 23, Issue 5, pages 967-976), alongside Ryan Marsh, Alexander Yule, Neele S. Dellschaft, Caroline L. Hoad, and others. This study examined the long-term effects of CFTR modulator therapy on gut microbiota and metabolome in individuals with cystic fibrosis. That same year, he was involved in 'Non-targeted analysis reveals hundreds of per- and polyfluoroalkyl substances (PFAS) in UK freshwater in the vicinity of a fluorochemical plant,' addressing environmental contamination. Also in 2024, he co-authored conference contributions such as 'WS04.03 Associations between nutrient intake, SCFA levels and the faecal microbiota in adults with cystic fibrosis: preliminary analysis' and 'P320 Impact of extended elexacaftor/tezacaftor/ivacaftor therapy on the gut microbiome in cystic fibrosis.' In 2023, his work appeared in 'Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome' in Microbiology Spectrum (Volume 11, Issue 5), where he performed formal analysis. An earlier publication from 2011 is 'Metabolic Profiling of Potential Probiotic or Synbiotic Cheeses by Nuclear Magnetic Resonance (NMR) Spectroscopy.' His research output has garnered 124 citations and 472 reads on ResearchGate, reflecting contributions to cystic fibrosis microbiology, environmental PFAS analysis, and analytical bioscience methodologies. He is associated with ORCID iD 0000-0003-0144-4327.